Health Care & Life Sciences » Biotechnology | Taxus Cardium Pharmaceuticals Group Inc.

Taxus Cardium Pharmaceuticals Group Inc.

Taxus Cardium Pharmaceuticals Group Inc.
Stock Exchange Other OTC
EPS
$0.29
Market Cap
$2 M
Shares Outstanding
14.37 M
Public Float
12.77 M

Profile

Address
11750 Sorrento Valley Road
San Diego California 92121
United States
Employees -
Website http://www.cardiumthx.com
Updated 07/08/2019
Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company . The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease; and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers.

Financials

View All

Christopher J. Reinhard
Chairman, President, CEO, CFO, Treasurer & CAO
Jia Yue Zhang
Executive Chairman